Personalis (PSNL) Azione Prezzo
Personalis Prezzo
Negli ultimi 8 anni Personalis ha aumentato il fatturato del 30,8% all'anno, raggiungendo 69,44 Mio. USD. Per Personalis, il margine netto del -117,0% risulta in calo rispetto al -76,5% di alcuni anni fa. Il target di prezzo di consenso a 12 mesi per Personalis è 16,25 USD, circa il 1,8% sopra il prezzo attuale di mercato. Su 11 analisti, 7 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Personalis Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Personalis Azione e analisi azionaria
Domande frequenti sull'azione Personalis
The business model of Personalis Inc is focused on genomic data and precision medicine. The company offers advanced genomic sequencing and analysis services to researchers, pharmaceutical companies, and healthcare providers. Personalis Inc leverages its expertise in genomics to analyze and interpret genetic information, helping customers gain insights into complex diseases and develop targeted therapies. With a comprehensive suite of proprietary technologies and a vast genomic database, Personalis Inc aims to revolutionize healthcare by delivering personalized solutions for better patient outcomes.
Personalis Inc is primarily active in the biotechnology industry.
The main competitors of Personalis Inc in the market include companies like Illumina, Inc., Foundation Medicine, Inc., and Exact Sciences Corporation.
Personalis Inc. is a renowned genomic sequencing and data analysis company based in California. Founded in 2010, Personalis specializes in advanced technologies that enable the study of genomics at an unprecedented scale. The company combines extensive reference data with state-of-the-art analytics to provide accurate and comprehensive genomic information. Personalis has built strong capabilities in cancer genomics, aiding in the development of personalized cancer therapies. With its proprietary biotechnology platforms, Personalis offers highly accurate sequencing capabilities as well as innovative systems for analyzing genomic data. Continuously expanding its expertise and collaborations, Personalis Inc. remains at the forefront of genomic research and precision medicine.
Personalis Inc has achieved several significant milestones throughout its journey. One noteworthy achievement is the successful completion of its initial public offering (IPO) in June 2019, which marked a pivotal moment for the company. Additionally, Personalis Inc has made remarkable strides in the field of advanced genomics, providing comprehensive and accurate genomic sequencing and interpretation solutions. The company's commitment to innovation has led to various collaborations with renowned pharmaceutical and biotechnology companies, further strengthening its market position and expanding its reach. Through its consistent dedication, Personalis Inc has established itself as a leading player in the genomics industry.
Personalis Inc is primarily present in the United States and operates globally.
Personalis Inc represents a strong commitment to leveraging genomics to advance the field of precision medicine. The company focuses on providing comprehensive, accurate, and reliable genomic data to empower healthcare professionals and researchers. Personalis Inc values innovation and excellence in developing cutting-edge technologies to deliver personalized insights into an individual's genetic makeup. With an emphasis on collaboration and integrity, Personalis Inc aims to drive breakthroughs in disease research, drug development, and patient care. By harnessing the power of genomics, Personalis Inc is dedicated to improving health outcomes and transforming the future of precision medicine.
Gli analisti fissano attualmente un prezzo obiettivo medio di 14,63 USD per l’azione Personalis (mediana: 16,25 USD), pari a -8,4 % rispetto all’ultimo prezzo. Il consenso si basa su 11 giudizi di analisti.
11 analisti valutano attualmente l’azione Personalis: 7 raccomandano l’acquisto, 4 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Personalis ricavi pari a 82,20 Mio. USD e un utile per azione di -1,05 USD.
Convertita al tasso di cambio attuale, l’azione Personalis quota 14,21 EUR (15,97 USD).
L’azione Personalis (PSNL) è quotata su 4 borse, tra cui: NASDAQ (PSNL), Frankfurt (04X.F), München (04X.MU), Düsseldorf (04X.DU).
Personalis Inc. is a company from the USA specializing in the development of personalized diagnostic and treatment solutions. The company operates in different sectors, each of which contributes uniquely to strengthening the company's life cycle. The first sector of Personalis is cancer genomics. The company has developed a platform that allows for the analysis of the genomics of cancer cells. The process involves sequencing DNA and RNA to obtain accurate information about the tumor type and its variations. With this information, Personalis develops strategies for the treatment of cancer patients and provides personalized treatment plans to its customers. Another important aspect of Personalis is genomics in immunology. Personalis utilizes its expertise to modulate the immune system of patients. The company has developed a technology that captures information about genetic variations in the immune system and uses this information to create personalized immunotherapies. This approach opens new avenues for developing treatment solutions for autoimmune diseases and other immune disorders. Personalis also has a services department that offers personalized diagnostic and treatment solutions to clinical and pharmaceutical customers. The company provides a wide range of services based on genomics, immunology, and other areas of personalized medicine. Personalis also serves the research sector through its services, equipping research laboratories in the biotechnology industry with the latest technologies to accelerate the progress of personalized medicine. The products offered by Personalis include the Cancer Genome Atlas (TCGA), a comprehensive dataset of DNA sequencing data provided to research laboratories to better understand cancer genomics and the mechanisms underlying cancer development. Personalis also offers the IMPACT test, a diagnostic platform that allows for the identification of genetic anomalies in cancer cells through sequencing. Personalis' business strategy focuses on the development of personalized diagnostic and treatment solutions, taking future advancements in medicine and biotechnology into account. Personalis aims to provide patients with the opportunity to receive the best possible treatment for their illness by leveraging the genetic information of their disease. In summary, Personalis Inc. offers innovative solutions for diagnostics and treatment through personalized medicine. With its expertise in genomics and immunology, the company covers various business fields. Personalis relies on the use of cutting-edge technologies to offer personalized solutions tailored to the specific needs of its customers. The company clearly positions itself as a leader in personalized medicine.
Il attesa fatturato di Personalis ammonta a 82,20 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Personalis ammonta a -96,57 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Personalis è attualmente -15,26. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Personalis.
Il rapporto prezzo/fatturato (P/S) di Personalis è attualmente 17,93. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Personalis.
Il Quality Score AlleAktien per Personalis è 2/10.
L'ISIN di Personalis è US71535D1063. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Personalis è A2PLTK. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Personalis è PSNL. Con questo simbolo di borsa vengono negoziate le azioni Personalis in borsa.
Azione Personalis
Gruppo di pari di Personalis
Personalis Ticker
Personalis FIGI
Altre metriche e analisi di Personalis in Deep Dive.
La nostra analisi azionaria dell'azione Personalis include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Personalis. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: